Sign Out
In a phase III trial the safety of Idarucizumab (Praxbind) has been evaluated in 503 patients, who had uncontrolled bleeding or required emergency surgery or procedures and were under treatment with Dabigatran etexilate (Pradaxa), as well as in 224 volunteers in phase I trials.
No adverse reactions have been identified.
Continue with Google